Investigating the effect of boswellic acid in acute ischemic stroke patients

Investigating the effect of boswellic acid on the clinical outcomes of patients with acute ischemic stroke

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231015059724N1

Enrollment

Registered

2023-10-24

Start date

2023-11-22

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke. Cerebral ischemic stroke

Interventions

Intervention 1: Intervention group: Patients in the intervention group, in addition to routine stroke treatments that include anti-ischemic drugs, will receive oral boswellic acid 360 mg tablets from

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with acute ischemic stroke Age between 18 and 80 years Hospitalization on the first day of symptoms A score between 5-21 before treatment based on the National Institutes of Health stroke scale (NIHSS)

Exclusion criteria

Exclusion criteria: Receiving alteplase or retplase in the hospital NIHSS score above 21 and loss of consciousness The presence of gastrointestinal complications that make it impossible to take drug.

Design outcomes

Primary

Measure	Time frame
Function score based on NIHSS. Timepoint: The first day of hospitalization (before the intervention) and one month after the intervention. Method of measurement: NIHSS questionnaire.;Erythrocyte sedimentation rate (ESR). Timepoint: The first day of hospitalization (before the intervention) and one month after the intervention. Method of measurement: Laboratory kit based on the Westergren test.;C-reactive protein (CRP). Timepoint: The first day of hospitalization (before the intervention) and one month after the intervention. Method of measurement: Laboratory kit based on agglutination test.;White blood cell count (WBC). Timepoint: The first day of hospitalization (before the intervention) and one month after the intervention. Method of measurement: Cell counter.;Red blood cell count (RBC). Timepoint: The first day of hospitalization (before the intervention) and one month after the intervention. Method of measurement: Cell counter.;Hemoglobin (Hb). Timepoint: The first day of hospitalization (before the intervention) and one month after the intervention. Method of measurement: Cell counter.	—

Measure

Time frame

Function score based on NIHSS. Timepoint: The first day of hospitalization (before the intervention) and one month after the intervention. Method of measurement: NIHSS questionnaire.;Erythrocyte sedimentation rate (ESR). Timepoint: The first day of hospitalization (before the intervention) and one month after the intervention. Method of measurement: Laboratory kit based on the Westergren test.;C-reactive protein (CRP). Timepoint: The first day of hospitalization (before the intervention) and one month after the intervention. Method of measurement: Laboratory kit based on agglutination test.;White blood cell count (WBC). Timepoint: The first day of hospitalization (before the intervention) and one month after the intervention. Method of measurement: Cell counter.;Red blood cell count (RBC). Timepoint: The first day of hospitalization (before the intervention) and one month after the intervention. Method of measurement: Cell counter.;Hemoglobin (Hb). Timepoint: The first day of hospitalization (before the intervention) and one month after the intervention. Method of measurement: Cell counter.

—

Secondary

Measure	Time frame
Complications. Timepoint: One month after the intervention. Method of measurement: Physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Rezvan Norouzzadeh

Oroumia University of Medical Sciences

norouzzadeh.r@umsu.ac.ir+98 44 3345 7286

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026